Sarepta Therapeutics/$SRPT
1D1W1MYTD1Y5YMAX
Capital at risk
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
- Ticker
- $SRPT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 835
- Headquarters
- Cambridge, United States
- Website
- www.sarepta.com
SRPT Metrics
BasicAdvanced
$2.2B
-
-$1.32
0.26
-
Price and volume
Market cap
$2.2B
Beta
0.26
52-week high
$25.32
52-week low
$14.68
Average daily volume
3.2M
Financial strength
Current ratio
4.422
Quick ratio
2.44
Long term debt to equity
68.455
Total debt to equity
69.539
Interest coverage (TTM)
-0.87%
Profitability
EBITDA (TTM)
-17.533
Gross margin (TTM)
19.11%
Net profit margin (TTM)
-6.92%
Operating margin (TTM)
-3.15%
Effective tax rate (TTM)
-4.43%
Revenue per employee (TTM)
$2,360,000
Management effectiveness
Return on assets (TTM)
-1.13%
Return on equity (TTM)
-9.48%
Valuation
Price to revenue (TTM)
1.102
Price to book
1.45
Price to tangible book (TTM)
1.48
Price to free cash flow (TTM)
29.015
Free cash flow yield (TTM)
3.45%
Free cash flow per share (TTM)
0.722
Growth
Revenue change (TTM)
-20.44%
Earnings per share change (TTM)
119.75%
3-year revenue growth (CAGR)
25.31%
10-year revenue growth (CAGR)
108.81%
3-year earnings per share growth (CAGR)
-49.64%
10-year earnings per share growth (CAGR)
-13.09%
What the Analysts think about SRPT
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
Analyst projections of the future price of Sarepta Therapeutics stock.
Bulls say / Bears say
Sarepta generated $328.7 million of product revenue in Q2 2026, including $98.1 million from ELEVIDYS, demonstrating that the company retains meaningful commercial traction despite the gene therapy’s safety overhang. (Q2 2026 Results)
Sarepta held $945.0 million in cash, cash equivalents, restricted cash, and investments as of June 30, 2026, providing substantial liquidity to fund operations and advance its pipeline while limiting near-term financing pressure. (SEC Form 10-Q)
The FDA accepted Sarepta’s supplemental applications for VYONDYS 53 and AMONDYS 45 for filing in June 2026, preserving a potential regulatory and commercial catalyst for the company’s established exon-skipping portfolio. (SEC Form 10-Q)
ELEVIDYS remains commercially unavailable for non-ambulatory Duchenne patients while Sarepta seeks FDA agreement on whether sirolimus data can support resuming dosing, leaving a major population and regulatory outcome uncertain. (SEC Form 10-Q)
Sarepta disclosed that the ESSENCE confirmatory trial for VYONDYS 53 and AMONDYS 45 failed to achieve statistical significance on its primary endpoint, creating risk for the durability and labeling of its exon-skipping franchise. (SEC Form 10-Q)
Regenxbio and the University of Pennsylvania filed patent litigation alleging that Sarepta’s AAV gene-therapy manufacturing process infringes their cultured-host-cell technology patents, creating potential legal costs, royalties, or operational constraints. (SEC Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
SRPT Financial Performance
Revenues and expenses
SRPT Earnings Performance
Company profitability
Upcoming events
No upcoming events
SRPT News
AllArticlesVideos
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Benzinga2 days ago
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Reuters2 days ago
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire1 week ago
Funds containing SRPT
AllUSDEURGBP
Fund name | Fund size | $SRPT weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.18% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.18% |
iShares Healthcare Innovation£DRDR | £1B | 0.18% |
iShares Ageing Population€AGED | €822M | 0.14% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.